|
|
 |
|
|
|
|
| Company name |
|
Olympus Terumo Biomaterials Corp. |
|
| Representative |
|
Hitoshi Mizuno, President |
|
| Head Office |
|
Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan
|
|
| Business activities |
|
Research and development relating to biomaterials and regenerative medicine, including ceramic bone substitute and collagen, and manufacture and sales of these products |
|
| Capitalization |
|
72,070,000 yen |
|
| Ownership |
|
Olympus 66.6%(192,000 shares), Terumo 33.4%(96,290 shares) |
|
| Business commencement |
|
September 1, 2004 |
|
| Employees |
|
Approximately 85 (as of January 1, 2010) |
|
| Officers |
|
| President |
|
Hitoshi Mizuno |
| Vice President |
Toshio Suzuki |
| Director |
Kazuhisa Yanagisawa |
| Director |
Hisashi Mori |
| Director |
Shinjiro Sato |
| Auditor |
Tadao Imai |
| Auditor |
Kiyoshi Makita |
|
|
| Financing bank |
|
Sumitomo Mitsui Banking Corporation |
|
 |
|
| |
|
| October 1, 2004 |
Olympus Biomaterial Corp. was established |
| September 1, 2005 |
Artificial bone material business was transferred from
Sumitomo Osaka Cement Co., Ltd. |
| December 14, 2006 |
Agreement of new biomaterial joint venture with collagen business of Terumo Corporation |
| January 1, 2007 |
Mishima plant was completed |
| April 1, 2007 |
Company name was changed to Olympus Terumo Biomaterials Corp. |
|
|
|
